Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 11, 2023

Changes in Cardiac and Vascular Haemodynamics as Potential Mediators of Cardiovascular and Kidney Outcomes With Empagliflozin in Type 2 Diabetes

Journal of Diabetes and its Complications


Additional Info

Journal of Diabetes and its Complications
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
J Diabetes Complicat 2023 Aug 17;37(9)108588, BK Krämer, SJ Hauske, R Chilton, JFE Mann, L Gullestad, D Fitchett, M Mattheus, D Steubl, C Wanner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading